Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Data presented at AAIC 2025 from a phase 2 study suggest that ABvac40 may slow cognitive decline in patients with Alzheimer disease, particularly among those who developed higher antibody levels.

Alzheimer Vaccine ABvac40 Shows Potential to Slow Cognitive Decline in Phase 2 Study

UCB's bepranemab shows promise in slowing tau accumulation in early Alzheimer disease, marking an advancement in tau-targeted therapies.

Anti-Tau Agent Bepranemab Slows Tau Accumulation in Phase 2 TOGETHER Trial

Videos

The director of neurosurgical pain division at Allegheny General Hospital highlighted the push to intervene earlier with neurosurgical treatments for chronic pain, including diabetic neuropathy. [WATCH TIME: 4 minutes]

Rethinking When to Refer for Pain Surgery: Nester Tomycz, MD

Here's some of what is coming soon to NeurologyLive® this week. 

This Week on NeurologyLive® — August 4, 2025

, has been with the team since September 2022. Follow her on Twitter 

The associate professor of neurology at Icahn School of Medicine at Mount Sinai discussed the clinical and scientific advantages of blood-based biomarkers over imaging for Alzheimer disease. [WATCH TIME: 5 minutes]

Debating on the Clinical Utility of Blood-Based Biomarkers for Alzheimer Diagnosis: Fanny Elahi, MD, PhD

Findings from a new study from Mayo Clinic may offer clinicians a straightforward metric–lesion resolution–to aid them in distinguishing MOGAD from MS in routine clinical practice.

Mayo Clinic Study Uses MRI Characteristics to Differentiate MOGAD From MS With High Accuracy

The associate professor of neurology at Mayo Clinic Rochester talked about using artificial intelligence-electrocardiogram at baseline to predict adverse vascular events in patients with migraine. [WATCH TIME: 5 minutes]

Exploring Use of AI Tools for Cardiovascular Risk Prediction in Migraine: Chia-Chun Chiang, MD

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

AAIC 2025

CMSC 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Clinical

SUP-22-NRD0184 - /clinical/movement-disorders

A Reliable Option for Reversing Morning Akinesia for Patients With Parkinson Disease

A Reliable Option for Reversing Morning Akinesia for Patients With Parkinson Disease

Newsletter